Thyrotropin-releasing hormone (TRH) receptor (TRHR) is a G-protein-coupled receptor playing a crucial role in the anterior pituitary where it controls the synthesis and secretion of thyroidstimulating hormone and prolactin. Its widespread presence not only in the central nervous system, but also in peripheral tissues, including thymus, indicates other important, but unknown, functions. One hypothesis is that the neuropeptide TRH could play a role in the immune system. We report here that the human TRHR promoter contains 11 putative response elements for the haematopoietic transcription factor c-Myb and is highly Mybresponsive in transfection assays. Analysis of Myb binding to putative response elements revealed one preferred binding site in intron 1 of the receptor gene. Transfection studies of promoter deletions confirmed that this high-affinity element is necessary for efficient Myb-dependent transactivation of reporter plasmids in CV-1 cells. The Myb-dependent activation of the TRHR promoter was strongly suppressed by expression of a dominant negative Myb-Engrailed fusion. In line with these observations, reverse transcriptase PCR analysis of rat tissues showed that the TRHR gene is expressed both in thymocytes and bone marrow. Furthermore, specific, high-affinity TRH agonist binding to cell-surface receptors was demonstrated in thymocytes and a haematopoietic cell line. Our findings imply a novel functional link between the neuroendocrine and the immune systems at the level of promoter regulation.
INTRODUCTION
Thyrotropin-releasing hormone (TRH) is a tripeptide (pGluHis-Pro-NH 2 ; where pGlu stands for pyroglutamic acid) that is released from the hypothalamus and transported via the portal vascular system to the anterior pituitary where it stimulates the release of thyroid-stimulating hormone (TSH) and prolactin from the anterior pituitary [1, 2] . In addition to its classical function as a releasing hormone, the distribution of TRH and its receptor indicates supplementary roles. TRH and TRH receptor (TRHR) are found distributed throughout the central and peripheral nervous systems as well as in other tissues [3] [4] [5] [6] including thymus [6] and small intestine epithelial cells [7] , consistent with its proposed role in the immune system. cDNAs encoding the highly conserved TRHR have been cloned from mouse, rat and hamster cell lines [8] [9] [10] , from human brain [11] and from avian and bovine tissues [12, 13] . This receptor is now also designated TRHR1, to be distinguished from TRHR2, a recently discovered subtype of the rat TRH receptor, 51 % identical to TRHR1 but with a distinct mRNA tissue distribution [14, 15] .
We have reported previously the cloning of the gene encoding the human TRHR [16] . The gene encompasses 35 kb and the open reading frame was found to be interrupted by a large intron of 31 kb with an additional 0.5 kb intron in the 5 -untranslated region. Sequencing of 2.5 kb of promoter region DNA allowed the identification of elements that may contribute to the regulation Abbreviations used: TRH, thyrotropin-releasing hormone; TRHR, TRH receptor; MeTRH, methylated TRH; TSH, thyroid-stimulating hormone; DBD, DNA-binding domain; MRE, Myb-responsive element; tk, thymidine kinase; EMSA, electrophoretic mobility-shift assay; RT-PCR, reverse transcriptase PCR. 1 To whom correspondence should be addressed (e-mail vilborg.matre@biokjemi.uio.no).
of the TRHR gene expression. One transcription start site was mapped to position −885 upstream of the putative translation start site [17] . Nonetheless, cell-type-specific promoter activity was found within a fragment smaller than this (− 770 to + 1), implying not only multiple transcription start sites, but also that important regulatory elements may be present in the first intron of the gene [16] . This intron 1 included two potential recognition elements for the pituitary transcription factor Pit-1, both of which were found to bind a protein factor in extracts from rat pituitary tumour cells [16] . These Pit-1 sites are likely to be important determinants for the cell-type-specific expression of the receptor gene in the anterior pituitary. In addition, two glucocorticoid response elements were identified and found to be necessary for transcriptional regulation of the TRHR gene by glucocorticoids [18] . The analysis of the TRHR promoter also revealed several potential binding sites for transcription factors that normally exert their functions during proliferation and differentiation of haematopoietic cells. Cells of the immune system have been found to contain receptors for neuroendocrine hormones and can also be considered a source of pituitary and hypothalamic peptides (reviewed in [7, [19] [20] [21] ). For TRH signalling in particular, it was reported that a proper T-cell-dependent immune response is critically dependent on the early activation of TRH and prolactin, suggesting an important relationship between the immune and endocrine systems [22] . To our knowledge, the role of shared transcriptional control in the circuitry between the immune system and the neuroendocrine system has so far not been explored. The present study addresses whether the TRHR promoter really contains functional elements for a haematopoietic transcription factor, focusing on putative response elements for c-Myb.
The c-Myb transcription factor regulates the proliferation, differentiation and apoptosis of immature lymphoid and myeloid cells [23] . In addition to its well-studied role in myeloid cells, c-Myb also plays a central role in T-cell development and function [24] . While resting T-cells express very low levels of c-Myb protein, T-cell activation leads to induction of c-Myb expression [25] . c-Myb is also expressed at high levels in immature thymocytes and may be a regulator of T-cell differentiation [26] . Transgenic mice with dominant interfering Myb alleles were found to have partially blocked thymopoiesis and proliferation of mature T-cells was inhibited [27] . Parts of this effect may be related to the regulation of the bcl-2 gene by c-Myb [28] . A T-cellspecific transcriptional enhancer of the human T-cell receptor δ gene also contains a highly critical binding site for c-Myb that is essential for enhancer activity [29] . Similarly, in the locus control region ('LCR') in the human adenosine deaminase (ADA) gene first intron, c-Myb acts as an organizer of thymocyte-specific gene expression [30] . The retroviral v-Myb was also found to be oncogenic in T-cells [31] . Finally, a study of homozygous null c-Myb/Rag1 chimaeric mice concluded that c-Myb plays an important role at multiple stages of haematopoiesis, and is essential at a specific stage early in T-cell development just before the oligopotent thymocytes mature into the definitive T-cell precursors [24] .
In the present work we have addressed the role of the haematopoietic transcription factor c-Myb in the activation of the TRHR promoter. Analysis of 11 putative Myb-responsive elements (MREs) in the human TRHR promoter pinned down a single MRE in the first intron that plays a particularly important role in the activation of the receptor gene. The TRHR promoter was found to be Myb-responsive and fragments from intron 1 conferred Myb-responsiveness on a heterologous thymidine kinase (tk) promoter. Expression analysis in rat demonstrated the presence of TRHR mRNA in thymocytes, bone marrow and in the rat natural-killer cell line RNK-16. This expression was shown to be functional as evidenced by TRH binding to surface receptors on thymocytes and RNK-16 cells. Altogether, these data suggest a novel link at the transcriptional level between the neuroendocrine and haematopoietic systems.
EXPERIMENTAL

Cell culture and reagents
CV-1, COS-1, HeLa, GH 1 2C 1 and GH 4 C 1 cells were cultured in Dulbecco's modified Eagle's medium with 10 % fetal calf serum. CV-1, COS-1 and HeLa cells were supplemented with 20 mM glutamine, penicillin and streptomycin. RNK-16 cells were cultured in RPMI 1640 medium with 10 % fetal calf serum, penicillin and streptomycin. Cells were grown under 5 % CO 2 in a humidified atmosphere. All culture media, sera and other additions were from Life Technologies.
Effector and reporter plasmids
The mammalian expression plasmids encoding full-length murine c-Myb (pEQP2-CMV-c-Myb [32] ) and truncated murine c-Myb [residues 1-360; pEQP2-CMV-c-Myb(1-360)] were kind gifts from Dr B. Lüscher, Institut für Biochemie, Klinikum der RWTH, Aachen, Germany. The dominant-negative effector pSCDMS/MEnT encodes the murine DNA-binding domain (DBD) fused to the Drosophila Engrailed transcription repressor domain [27] and was a kind gift from Dr K. Weston, CRC Centre for Cell and Molecular Biology, Chester Beatty Laboratories, London, U.K. The luciferase reporter constructs pGL2/tk-3xGG and pGL2/tk-3xTT have been described in [33] . The reporter plasmids pGL2/tk-MREcA, pGL2/tk-MREcB and pGL2/tk3xTR10 were constructed by inserting one of the following fragments into pGL2/tk: a PCR product spanning the −2160 to −2047 region or the −404 to −145 region of the human TRHR promoter, or a duplex oligonucleotide with the sequence 5 -GCATTATAACCGTCACTAACCGTCACTAACCGTCACT-TAGCGCGAGCT-3 , where the repeated MRE-TR10s (MRE-TR10 is one of the putative response elements for c-Myb; see the Results section for details) are underlined. The reporter plasmids with upstream deletions (designated pGL2b-TRHR-n) were constructed by inserting in pGL2basic (Promega) PCR products spanning the region from n to + 1 (initiator ATG position) from the TRHR promoter (where n indicates the deletion endpoints, −2530, −2250, −2000, −1750, −1500 and −1250). Reporter plasmids with internal deletions were all derived from pGL2b-TRHR-1250 using a common strategy to introduce deletions in intron 1. The plasmid was digested with SacII (−819) and BclI (−139) and the excised fragment replaced with a PCR fragment spanning the region from SacII to an engineered BclI site introduced by PCR in the positions −162, −251, −351 and −449, giving rise to the plasmids I-A, I-B, I-C and I-D respectively. Mutagenesis of MRE-TR10 was performed by using the QuikChange site-directed mutagenesis kit (Stratagene) on a SacII-XhoI subfragment of pGL2b-TRHR-1250. All constructs generated by PCR were verified by sequencing.
Expression of c-Myb proteins
Whole-cell extracts of Myb-transfected COS-1 cells were prepared as described previously [32, 33] . The minimal DBD of human c-Myb, R 2 R 3 (residues 89-104), designated c-Myb-DBD, was expressed in Escherichia coli and purified as described in [34] .
Electrophoretic mobility-shift assay (EMSA)
DNA binding was monitored by EMSA. The mim-1 A site oligonucleotide was labelled and purified as described in [35] . Unlabelled double-stranded oligonucleotides for competition were similarly annealed, filled in and PAGE-purified. Binding reactions with recombinant c-Myb or whole-cell extracts of Mybtransfected COS-1 cells were performed as described previously [33] . Typically 1-3 µl of COS-1 cell extract (10 µg of protein) or 20 fmol of purified recombinant c-Myb R 2 R 3 was used per binding reaction. 5 γ -32 P-labelled DNA oligonucleotide probe (10 fmol) was added and the binding mixture (total volume 20 µl) was incubated for 10 min at 25
• C before electrophoresis.
Transactivation assays in mammalian cells
CV-1 cells were transfected with Fugene (Roche Molecular Biochemicals) and HeLa cells using Lipofectamine (Life Technologies) as recommended by the manufacturers. Cells were seeded the day before at (1-2) × 10 5 cells/plate in 35 mm plates. Cells were transfected with the indicated amounts of effector and reporter plasmids in combinations indicated in the Figures. Cells were lysed and scraped into 250 µl of reporter lysis buffer (Promega). All lysates were analysed for luciferase activity using either a standard or a dual-luciferase assay kit as described by the manufacturer (Promega). Comparable Myb expression in transfected cells was verified by Western analysis.
Isolation of cells from the bone marrow, thymus, spleen and lymph nodes
Rats, strain PVG, age 7-10 weeks, were killed using CO 2 gas. Cells and tissues were immediately dissected out and placed in sterile ice-cold PBS, pH 7.4. The tissues were disrupted and homogenized by cutting and squeezing through a nylon membrane (cell strainer) and centrifuged. The pellet was washed twice in ice-cold PBS and immediately lysed in a guanidinium thiocyanate solution consisting of 5 M guanidinium thiocyanate, 25 mM sodium citrate (pH 7.0), 0.5 % sodium larcosyl sulphate and 0.7 % β-mercaptoethanol. For isolation of natural killer cells from the spleen the procedure of [36] was followed.
RNA isolation and reverse transcriptase PCR (RT-PCR) analysis
Total RNA was prepared from different tissues and cell lines [37] . Total RNA (3 µg) was reverse transcribed using Moloney murine leukaemia virus reverse transcriptase (Promega). In the PCR reactions, 20 % of the cDNA served as template in 50 µl of 1 × Vent buffer in the presence of 0.1 mM of each dNTP and 0.2 µM of each primer. The primers were rTRHR-Forward (5 -TTACCGGAATTCATATGGAGAATGAAACCGT-3 ) and rTRHR-Reverse (5 -GCGCATGGATCCTATCATATTTTCTCC-TGTTTGGCAG-3 ). RNA samples from GH 4 C 1 and GH 1 2C 1 cells were used as positive and negative controls respectively. Vent DNA polymerase (0.6 units; New England Biolabs) was added after a hot start of 5 min at 94
• C. The PCR program proceeded as follows: 1 min at 94
• C, 1 min at 60 • C and 2 min at 70
• C for 34 cycles, and finally 10 min at 70 • C.
TRH-binding assay
The assessment of the binding of tritium-labelled methylated TRH ([ 3 H]MeTRH) was performed according to established methods [38] .
RESULTS
The TRHR1 promoter contains 11 potential Myb-responsive elements arranged in two clusters
Previous reports have suggested that the TRHR is expressed not only in the anterior pituitary, but also in rat peripheral tissues including thymus [6] and small intestine epithelial cells [7] , indicating a thus-far unknown role in the immune system. We were intrigued by the finding of response elements for the haematopoietic transcription factor c-Myb in the TRHR promoter. When a region of 2.5 kb in the TRHR gene upstream of the translation start site was sequenced, we identified 11 putative response elements for c-Myb, all fitting the consensus sequence YAACNG (Figure 1 ). Three sites were clustered in a 100 bp region far upstream (−2161 to −2059) and four were clustered in a 250 bp region in the first intron (−397 to −155; Figure 1 , top panel). In addition, four other potential sites were found scattered throughout the sequenced region. We named the two clustered regions MRE-cluster A and MRE-cluster B and designated the putative sites MRE-TR1 to MRE-TR11, as listed in Figure 1 (bottom panel). From the theoretical scores for all the potential sites (estimated using a matrix procedure [39] ), we predicted that MRE-cluster A contains two strong (MRE-TR2 and MRE-TR3) and one weak (MRE-TR1) MREs, whereas MRE-cluster B contains three reasonably strong sites (MRE-TR7, -TR9 and -TR10) and one weak one (MRE-TR8). The analysis of scores furthermore predicted that the four scattered MREs are either of modest strength (MRE-TR4, -TR5 and -TR6) or very weak (MRE-TR11).
EMSA of putative MREs
To assess which of the putative MREs were in fact recognized by c-Myb, oligonucleotides corresponding to the elements with the highest score ( 2.40) were labelled and used as binding probes for recombinant c-Myb-DBD. The MRE-TR1 oligonucleotide was also labelled as a representative of a weaker site (score 1.90). A reasonable correlation between theoretical scores and efficiency of binding was observed (Figure 2, left-hand panel) . While the MRE-TR1 probe gave barely detectable binding, strong binding was observed for MRE-TR2, MRE-TR3, MRE-TR7 and MRE-TR10. Somewhat weaker binding was observed for MRE-TR9, as expected (score 2.40). The binding data indirectly supports our assumption that MREs with a score lower than 2.4 (MRE-TR4, -TR5, -TR6 and -TR11) are not major binding sites although they may contribute to Myb-responsiveness in combination with stronger sites. The most efficiently bound probes appeared to be MRE-TR2 (score 2.99) and MRE-TR10 (score 2.66).
To verify that the sites bound by recombinant c-Myb-DBD were also recognized by Myb proteins expressed in mammalian cells, we analysed the labelled MRE oligonucleotides for binding using extracts from Myb-transfected cells as protein source. COS-1 cells were transfected by an expression plasmid pEQP2-CMVc-Myb(1-360) and whole-cell extracts were used as a source for Myb proteins [32] . Each probe was tested in the absence and presence of an excess of unlabelled Myb-specific oligonucleotide to verify that the retarded complexes showed specific binding. In this system, essentially the same pattern of binding affinities was seen as with the recombinant protein, but the selectivity seemed to be more stringent than with recombinant proteins (Figure 2 , righthand panel). Thus the best MREs (MRE-TR2, MRE-TR3, MRE-TR7 and MRE-TR10) all gave rise to retarded bands, but now MRE-TR10 was clearly superior to the other MREs with respect to binding affinity. In fact, the complex formed on MRE-TR10 was as strong as that obtained with the positive control probe from the mim-1 gene (Figure 2 , right-hand panel, compare lanes 11 and 13). The increased stringency also resulted in a rather weak binding to MRE-TR7 and no detectable binding to MRE-TR9. We conclude that among the 11 putative Myb-binding elements in the TRHR1 promoter, one site (MRE-TR10) was clearly a preferred binding site for c-Myb.
Regions of the human TRHR1 promoter harbouring MRE-TR10 mediate Myb-dependent transactivation
To test whether the regions harbouring the best MRE sites also conferred Myb-dependent transactivation, two luciferasereporter plasmids were constructed harbouring either of the MREcluster A or MRE-cluster B regions upstream of the tk basal promoter. These reporters were co-transfected with two different c-Myb effector plasmids into Myb-negative CV-1 cells. One effector encoded full-length c-Myb, the other encoded a chimaera of the minimal DBD of human c-Myb (R 2 R 3 ) fused to the strong transactivation domain of herpes simplex virus VP16. As shown in Figure 3 (top panel) , the cluster A gave weak Myb-dependent transactivation (4.3-fold), only slightly above the Myb response of The human TRHR gene sequence upstream of the ATG initiation codon was analysed for the presence of putative MREs using matrix analysis [39] . Top panel: the scores calculated for each putative MRE (designated TR1-TR11) are plotted along the TRHR gene sequence to illustrate the locations and clustering of the MRE elements. For comparison, a similar plot for the Myb-responsive mim-1 gene [50] is included (box). Bottom panel: list of putative MRE sequences (TR1-TR11) in the human TRHR gene promoter including matrix scores [39] . The oligo column shows which elements were used to probe for binding to c-Myb. 1 and 2) , MRE-TR2 (lanes 3 and 4) , MRE-TR3 (lanes 5 and 6), MRE-TR7 (lanes 7 and 8), MRE-TR9 (lanes 9 and 10), MRE-TR10 (lanes 11 and 12) and mim-1 A reference probe (lanes 13-15) . Lane 15 shows the migration of probe only.
Figure 3 MRE clusters from the TRHR promoter mediate Myb-dependent transactivation
CV-1 cells were co-transfected with the indicated combinations of Myb effector and MRE reporter plasmids. The effectors used expressed either full-length c-Myb (black columns, cM-FL; effector, pEQP2-CMV-c-Myb) or the c-Myb DBD fused to the VP16 transactivation domain (hatched columns, cM-VP16; effector, pCIneo-R 2 R 3 VP16). As a negative control we used empty expression vector (white columns, Vector; effector, pCIneo). Top panel: the luciferase reporters analysed in this panel contained either the cluster A or B region of the TRHR promoter (reporters pGL2/tk-MREcA or pGL2tk/MREcB respectively, see text for details). As negative control the reporter pGL2/tk-3xTT was used [33] . Bottom panel: two reporters with multimerized MREs were compared. pGL2/tk-3xTR10 (black columns) contained three tandem copies of the TR10 element and pGL2/tk-3xGG (hatched columns) contained three tandem copies of the strong mim-1 A site (positive control [33] ). In both panels results are expressed in relative luciferase units (RLU). In all transfections CV-1 cells were transfected with 0.2 µg of effector and 1.0 µg of reporter plasmid.
the negative control reporter plasmid (3.2-fold) containing three copies of a very weak MRE. The MRE-cluster B conferred a significantly higher Myb-dependent transactivation, in particular with the R 2 R 3 VP16 construct (5.5-and 11.4-fold respectively). Thus the cluster in intron 1 encompassing the MRE-TR10 element conferred a clear Myb-dependent transactivation on the reporter.
To test the role of the MRE-TR10 element, a reporter plasmid was constructed harbouring only the MRE-TR10 element (in three copies). When this reporter was co-transfected with a c-Myb effector plasmid into CV-1 cells, strong Myb-dependent transactivation was measured demonstrating that this element alone was sufficient to mediate strong Myb-dependent promoter activation (Figure 3, bottom panel) . When compared with the reference reporter pGL2/tk-3xGG (with the strong mim-1 A site in three copies), the pGL2/tk-3xTR10 reporter gave apparently as high or even higher transactivation.
The TRHR1 promoter is Myb-responsive
To test whether the TRHR1 promoter itself was Myb-responsive, we constructed a TRHR1-luciferase chimaera with the region from −1250 to + 1 (initiator ATG position) from the TRHR1 promoter fused to the luciferase reporter gene. When this reporter was co-transfected with the two c-Myb effector plasmids in CV-1 cells, strong Myb-dependent activation was observed for both effectors (results not shown, but see Figure 4 , top-right panel, below). This shows that not only does this promoter contain Mybresponsive elements active in the context of a heterologous basal promoter (tk), but the TRHR1 promoter is itself highly Mybresponsive.
Supporting evidence was obtained by examining activation of the TRHR1 promoter in transfected HeLa cells in the presence or absence of a dominant-negative Myb-Engrailed fusion. Again introduction of a Myb-effector plasmid caused activation of the TRHR1 promoter, whereas co-expressing the dominant-negative Myb abolished this activation almost completely (Figure 4 , topleft panel). The dominant-negative construct alone also reduced the background level observed in this cell line, most likely by binding and repression through the many MREs present in the promoter.
Dissection of the TRHR promoter: a prominent role for the TR10 element
In an effort to map the Myb-responsive regions in the TRHR1 promoter, we constructed luciferase reporters driven by successive upstream deletions of the TRHR1 promoter and tested these in co-transfection experiments. Very similar Myb-responsiveness was observed with deletion endpoints at −2530, −2250, −2000, −1750, −1500 and −1250 (Figure 4, top-right panel) . The only consistent difference between these reporters was an increased basal promoter activity in the longest construct (−2530) compared with the rest. It seems that neither the MRE-cluster A (−2161 to −2059) nor the dispersed MREs in the upstream region make major contributions to the overall Myb-responsiveness of the TRHR1 promoter, consistent with the modest effect of MREcluster A observed in the enhancer analysis (Figure 3, top panel) .
Having found stronger activating effects of MRE-cluster B (Figure 3, top panel) and evidence for an important role for the TR10 element (Figures 2, right-hand panel, and 3 , bottom panel), we constructed successive internal deletions in intron 1 as well as a promoter construct where TR10 had been mutated as illustrated in Figure 4 (bottom panel). When these reporters were analysed in co-transfection experiments, a major decrease in Myb response was observed even with the smallest intron deletion ( I-A) where the TR10 element was removed. A very similar fall was observed when the TR10 element was mutated (Figure 4, bottom panel) . Larger intron deletions slightly only reduced the Myb response further, supporting a prominent role for the TR10 element in mediating Myb-responsiveness of the TRHR1 promoter. It is noteworthy that none of the constructs totally eliminated the Myb response, suggesting that some low-level residual responsiveness could be due to indirect effects or the presence of Myb-responsive elements outside the region of analysis. The slight activation of the 3xTT control construct (Figure 3, top panel) is consistent with this. 
TRHR1 is expressed in haematopoietic tissues and cell lines
To investigate whether TRHR1 was expressed in haematopoietic cells, total RNA was isolated from a selection of haematopoietic tissues and cell lines and analysed for presence of TRHR1-related sequences by RT-PCR and Southern blotting. As shown in Figure 5 (upper panel) a clear TRHR1-specific amplification product was detected using RNA from thymocytes. The amplicon was of the same order of intensity as obtained with the positive control RNA isolated from the receptor-positive pituitary adenoma cell line GH 4 C 1 . A haematopoietic cell line included in the experiment (the RNK-16 cell line) also showed high levels of expression. When subjected to Southern analysis, clear hybridization signals verified the TRHR1 specificity of the amplicons ( Figure 5, lower panel) . In addition, it revealed detectable expression of TRHR1 in both bone marrow and natural killer cells. On the other hand, no expression could be detected in GH 1 2C 1 cells (negative control), Peyer plaques, splenocytes or lymph node samples, even after prolonged exposure. This shows that TRHR1 is expressed in specific haematopoietic cells and tissues.
To verify that the detected mRNA expression led to the expression of functional receptors on the cell surface, we analysed the capacity of TRHR1-positive cells to bind specifically the TRH analogue [ 3 H]MeTRH. As expected from the RT-PCR profile, both thymocytes and RNK-16 cells showed specific binding of the agonist, as seen by competition with unlabelled TRH displacing in the naonmolar range ( Figure 6 ). This confirms that active TRHR1 is present on these cells. The haematopoietic cells had severalfold lower binding capacity, reflecting a much lower number of receptors compared with GH 4 C 1 cells. No binding was detected to splenocytes or lymphocytes (Figure 6 ) or to the receptor-negative pituitary cell line GH 1 2C 1 (results not shown). We conclude that thymocytes as well as the cell line RNK-16 express a single class of high-affinity binding sites for TRH.
DISCUSSION
We have in the present work shown that TRHR1 is expressed in important haematopoietic tissues such as thymus and bone marrow and provided evidence that the promoter of the human receptor is activated by the haematopoietic transcription factor c-Myb. Both findings point to a novel link at the transcriptional level between the neuroendocrine system and the immune system. Different experimental approaches were used to examine the hypothesis that c-Myb is an activator of human TRHR1. The multiplicity of binding sites for c-Myb, 11 within a region of 2 kb, is in itself one argument. Genome-wide analysis of transcription-factor-binding sites in Caenorhabditis elegans has revealed that multiplicity is a highly discriminating criterion for the biological relevance of response elements [40] . Secondly, several of the putative MREs were found to bind recombinant c-Myb. In addition, extracts from c-Myb-expressing cells gave specific complexes with several of the putative MREs, with TR10 as a particularly strong binding element. A DNA fragment from intron 1 harbouring the TR10 element conferred Mybresponsiveness on a heterologous tk basal promoter. The same observation was made using an isolated multimerized TR10 element. Furthermore, TRHR1's own basal promoter was found to be highly Myb-responsive in transient transfection experiments, and the activation was cancelled out by a dominant-negative Myb construct and strongly reduced upon deletion or mutation of the TR10 element.
Intron 1 seems to be an important regulatory region controlling TRHR expression. We have previously mapped two binding sites for the anterior-pituitary-specific transcription factor Pit-1 in intron 1 [16] . These most probably control tissue-specific expression of the receptor in the anterior pituitary. The strongest of these sites, Pit-1B, is located only 40 bp downstream of the strong TR10 MRE. We have previously also reported the identification of a response element for the glucocorticoid receptor in intron 1 (proximal GRE) [18] . Other predicted candidate sites are present, but remain to be investigated. Intron 1 thus seems to harbour multiple response elements probably controlling in a co-ordinated fashion both tissue-specific expression and responsiveness of the promoter.
Our expression analysis in rat tissues and cell lines showed that TRHR1 is indeed expressed in major haematopoietic tissues like thymus and bone marrow. These results confirm and extend the findings of Fukusumi et al. [6] , which showed by RT-PCR and Northern blot analysis that TRHR1 mRNA was expressed at relatively high levels in several peripheral tissues including thymus. The expression of TRHR1 in thymus was also confirmed by Montagne et al. [41] . Their finding in thymus of low levels of both TRH mRNA (corresponding to about 6 % of the level in the hypothalamus) and TRH peptide suggested that TRH may act locally in the thymus. Additional evidence comes from studies using a peptide-derived anti-TRHR1 antibody, also supporting the presence of TRHR1 in lymphoid tissues [42] . An important confirmation is also our present demonstration of TRH agonist binding to cell-surface receptors present on thymocytes and RNK-16 cells. Although the level of receptors expressed in these cells seems to be several-fold lower than what has been reported in the specialized pituitary adenoma cell line GH 4 C 1 , it could still be a level sufficiently high to play a functional role in thymocytes.
What could the biological function of TRH be in a peripheral tissue like thymus? One possible role is growth control since TRH has been reported to increase thymocyte cell proliferation in rats [43] . Similarly, Lesnikov et al. [44] made the interesting observation that a stereotactic electrolytic lesion of the anterior hypothalamic area in mice produced a rapid involution of the thymus and a reduction of lymphocytes in the peripheral blood, an effect that was prevented by postoperational administration of TRH or melatonin and which seemed to reflect a direct activity of TRH on thymic targets or binding sites on lymphocytes.
Another possibility is that TRH could act as a local hormone in one of the neuroendocrine circuits within the thymus and thus play an immunomodulatory role during an active immune response. A large body of work has established that intricate interactions of both a stimulatory and inhibitory nature exist between the neuroendocrine and immune systems (reviewed in [19] [20] [21] 45] ). Thymus is one central tissue in this respect [45] . Supporting evidence for a role of TRH in this network is the finding that a proper T-cell-dependent immune response requires the early activation of TRH and prolactin [22] . T-celldependent antigens elicited a rapid increase of hypothalamic TRH and TRHR1 mRNAs, while specific antibody production could be inhibited by intracerebro-ventricular injection of antisense TRH oligonucleotides. There is also evidence that TRH and TSH act as local hormones in the lymphoepithelial communication in the intestine, where the expression pattern of receptors for TRH and TSH suggested a hormone-mediated link between the lymphoid and non-haematopoietic components of the intestine [46] . Consistent with this, mice with a mutant TSH receptor (hyt/hyt mice) were found to have a selectively impaired intestinal T-cell repertoire [46] . It would have been interesting to study whether the high expression of c-Myb in the intestine [47, 48] also plays a role in controlling expression of TRHR in this organ. Another attractive line of investigation would have been to study links between mutations in the gene for the TRHR and impaired immune function. Mutations in TRHR causing reduced or absent receptor activity were found in a patient with isolated central hypothyroidism, but defects in immune function were not investigated [49] .
In conclusion, our study provides evidence for a novel functional link between the neuroendocrine and the immune systems operating at the level of promoter regulation. The neuroendocrine receptor TRHR1 seems to be transcriptionally regulated by the haematopoietic transcription factor c-Myb. This link is also reflected in TRHR1 being functionally expressed in haematopoietic tissues and cell lines.
